ESLA supply chain intelligence for Estrella Immunopharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Estrella Immunopharma, Inc. (ESLA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| EUREKA | EUREKA | 92% | On June 28, 2022, we entered into the License Agreement with Eureka and Eureka Therapeutics (Cayman), Inc. to license certain functions related to any T-cell products that incorporate (a) the ARTEMIS… |
| IMUGENE | IMUGENE | 90% | On October 29, 2021, Eureka entered into a collaboration agreement (the “Collaboration Agreement”) with Imugene, a clinical stage immuno-oncology company, to evaluate the use of CF33-CD19t in conjunc… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PLENTIFUL-LIMITED | PLENTIFUL-LIMITED | 62% | s AA Preferred Stock that was issued and outstanding immediately prior to the Effective Time was automatically converted into a number of shares of Estrella Common Stock (See Note 12); ● Each share o… |
| UPTD-TRADEUP-ACQUISITION-SPONSOR-LLC | UPTD-TRADEUP-ACQUISITION-SPONSOR-LLC | 62% | contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. License Agreement Pursuant to the License Agreement, we were obligated to make… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ESLA-DEBT-9359 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-06-30. |
| ESLA-DEBT | Debt stack $6,000 | 90% | Market cache reports total debt of $6,000. |